Cash-guzzling Horizon prices new offering
This article was originally published in Scrip
Horizon Pharma has priced a public offering of common stock and warrants and expects to raise $70 million in net proceeds, or $81 million if an over-allotment option is fully exercised. The offering, which is expected to close on 25 September, will involve the sale of units consisting of one share and a warrant to purchase 0.5 shares priced at $3.50. The company's share price has tumbled by 24% from $4.58 on 19 September before it disclosed its planned offering to $3.49 in mid-morning trading on 21 September following the pricing. The company's market cap was $118 million on 21 September 2012.
You may also be interested in...
Fundraising in the life sciences sector has been booming even as firms in many other industries are struggling to stay in business. Goodwin’s David Mardle is upbeat about the sector’s ongoing prospects – although M&A deals are currently proving tricky to complete.
See how much the CEOs and R&D heads of the world’s biggest pharma companies get paid, and how those companies are performing.
Merck & Co is gradually catching up with Roche in PD-1/L1 first-line triple-negative breast cancer treatment, but its presentation at ASCO on Keynote-355 includes mixed PFS results. Overall survival data will be key to Keytruda’s competitiveness.